Project Grant R21AI183079
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$428K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $233,736 to Washington University in St. Louis to elucidate how the DARG1 antitoxin senses and responds to bacterial virus (phage) infection. The research aims to determine which phage DNA metabolism processes are necessary for DARG1 to detect infection, and which DNA processes are sufficient to trigger DARG1's reaction in the absence...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of polymer-phage nanoparticle conjugates to treat antibiotic-resistant wound biofilm infections. The $593,860 award to the University of Massachusetts aims to create new phage-polymer nanoparticles that can more effectively penetrate and eradicate bacterial biofilms compared to free phage therapies. The...
This Project Grant award of $868,776.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to characterize a novel post-transcriptional regulator in the opportunistic pathogen Pseudomonas aeruginosa. The key objectives are to: Identify the direct regulatory targets of the RNA-binding protein PhaF under standard lab conditions, infection-relevant conditions, and in clinical isolates to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $453,750 to Tufts University School of Medicine to study how certain bacteriophages (viruses that infect bacteria) evade the protective mechanisms of bacteria, including some deadly pathogens like Vibrio cholerae. The project aims to determine the counter-defense mechanisms used by these phages and identify the...
This Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $197,646 to the University of California, San Diego (UC San Diego) to conduct research on enhancing bacteriophage function with coevolution and synthetic biology. The overall objective is to use experimental evolution to identify genetic changes in phages that enhance their ability to suppress bacterial growth,...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $112,077 to The Ohio State University to develop novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida species dual-species biofilms. The key objectives are to: 1) develop combination treatments using antimicrobial peptides and bacteriophages, and 2) genetically engineer P. aeruginosa...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $1,144,714 to the University of Illinois to conduct research aimed at discovering novel antibiotics for gram-negative pathogens. The primary goals are to identify physicochemical traits that allow antibiotics to evade efflux pumps in E. coli, P. aeruginosa, and A. baumannii, and then apply this knowledge to develop at...
The federal Project Grant award R21AI188434, totaling $226,253.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award supports research conducted by The Washington University, a private research institution located in Missouri, to study the modulation of neutrophil-endothelial interactions by the ADAM10 protein and its impact on Staphylococcus aureus infection. The goal is to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,388,838 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Research Foundation For The State University Of New York (RF SUNY) to optimize phage cocktail regimens for treating extensively drug-resistant Pseudomonas aeruginosa. The project aims to: 1) develop a quantification assay for the phage cocktail, 2) identify optimal phage combinations and administration patterns...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $173,030 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to President and Fellows of Harvard College. The grant, awarded on September 25, 2024, will fund the development of a novel assay for targeted isolation of environmental bacteriophages (phages) based on their receptor dependencies. The project aims to create a generalizable technique that allows selecting phages that require...